Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Travis Kelce downs whiskey shot on slice of bread at Kelce Jam without Taylor Swift
Ashanti and Nelly's relationship timeline: A look at the couple's on
The iconic fantasy film that catapulted a 17
Four people killed in a house explosion in southwestern Missouri
Amanda Holden reveals a huge secret about THAT nude appearance on her Heart FM breakfast show
France asks retailers to alert customers to cases of 'shrinkflation'
Swiatek beats Raducanu in Stuttgart quarters. Sabalenka loses to Vondrousova
Ben Whishaw lights up the Croisette as he joins his co
Hackers claim Belarus fertilizer plant infiltrated to demand political prisoner release
Elon Musk gets approval from FDA to implant his Neuralink brain chip into a second patient
BP defeated thousands of suits by sick Gulf spill cleanup workers. But not one by a boat captain